MIDWEST PEDIATRIC PHARMACY CONFERENCE
Akron Children’s Hospital
Friday October 21, 2016
Considine 1&2 Auditorium

Announcements:

Handout Information: Links to PDF versions of session handouts are provided within the schedule below.

CE Credit Information: In order to receive CE Credit, you must fill out an online post-session evaluation. The links are below within the schedule. You have until November 4, 2016 to fill out your evaluation. After Novermber 4, your credit will be uploaded to your NABP CPE Monitor Profile.

 

Agenda and Handouts

8:00 am Registration and Breakfast
8:30 am

Akron Children’s Hospital-The Story
Bill Considine, President and CEO Akron Children’s Hospital
​0180-0000-16-801-L04-P

Evaluation

At the end of the session, participants will be able to:

  1. Describe the history of Akron Children’s Hospital
  2. Discuss the structure of the Akron Children’s Hospital System
  3. List the mission and vision of Akron Children’s Hospital
9:00 am

Generalized Arterial Calcification of Infancy: What are the odds?
Kelsey Brown, Pharm.D. & Catherine Hobart, Pharm.D.
PGY1 Residents, Rainbow Babies and Children’s Hospital
​0180-0000-16-802-L01-P

Handout | Evaluation

At the end of the session, participants will be able to:

  1. Review the pathophysiology of Generalized Arterial Calcification of Infancy (GACI)
  2. Analyze treatment strategies and medication therapy for GACI
  3. Examine a patient case of GACI
  4. Evaluate efficacy of treatment in this patient case and future clinical scenarios
9:30 am

Refractory Status Epilepticus
Hilary Orr, Pharm.D., PGY2 Critical Care Resident
Kosair Children’s Hospital
​0180-0000-16-803-L01-P

​Handout | Evaluation

At the end of the session, participants will be able to:

  1. Review the pathology of refractory status epilepticus (RSE)
  2. Discuss the consequences associated with prolonged seizure activity
  3. Evaluate treatment options for RSE
  4. Design an optimal treatment regimen for patients with RSE
     
10:15 am Break
10:30 am

Implementation of a Febrile Neutropenia Guideline and Its Impact on Antibiotic Prescribing
Paris Balfour-Ducharme, Pharm.D. & Patricia Christoff, Pharm.D.
Dayton Children’s Hospital
​0180-0000-16-804-L01-P

​Handout | Evaluation

At the end of the session, participants will be able to:

  1. To briefly outline the Infectious Disease Society of America (IDSA) recommended strategies which have been adopted by the Antibiotic Stewardship Program at Dayton Children’s Hospital
  2. To review the guideline proposed by the American Society of Clinical Oncology for the management of fever and neutropenia in children with cancer
  3. To review the rationale behind the febrile neutropenia guideline developed at Dayton Children’s Hospital
  4. To discuss the impact on antibiotic prescribing following implementation of the guideline
11:00 am

Vaccine Updates: What’s New in 2016
Katee Miller, Pharm.D., PGY1 Resident
Akron Children’s Hospital
​0180-0000-16-805-L01-P

​Handout | Evaluation

At the end of the session, participants will be able to:

  1. Describe additions/modifications to the CDC 2016 routine pediatric immunization schedule and the 2016-2017 influenza season recommendations
  2. Discuss increasing efforts to promote vaccination of pediatric patients
  3. Assess the ordering process to accurately document proper vaccine storage and handling
11:30 am

Neonatal Abstinence Syndrome: Exploring the Unknown
Jessika Richards, Pharm.D., PGY2 Pediatrics Resident
University of Michigan Health System
​0180-0000-16-806-L01-P

​Handout | Evaluation

At the end of the session, participants will be able to:

  1. Describe the epidemiology and pathophysiology of NAS
  2. Examine the clinical and genetic factors contributing to inter individual response variability in NAS
  3. Discuss short and long term consequences of in utero exposure to drugs of abuse
  4. Recognize the impact of increasing NAS incidence on public health and health care utilization costs
12:00 pm

Town Hall/Lunch
​Clinical Dilemmas, Solutions, and Collaboration in Pediatric Pharmacy
Cassandra Karish, PharmD
Akron Children’s Hospital
​0180-0000-16-807-L04-P

Evaluation

At the end of the session, participants will be able to:

  1. Identify and discuss pertinent clinical/operational dilemmas in pediatric pharmacy
  2. Share organizational solutions to pertinent issues in pediatric pharmacy
  3. Collaborate on ways to provide effective, evidence based, patient centered care
12:45 pm

To wait or not to wait? Timing of Parenteral Nutrition in Critically Ill Pediatric Patients
Michelle Robosky, Pharm.D. & Kelsey Fink, Pharm.D., PGY2 Pediatric Residents
Nationwide Children’s Hospital
​0180-0000-16-808-L01-P

Handout | ASPEN Guidelines | NEJM Article 
Evaluation

At the end of the session, participants will be able to:

  1. Review literature surrounding early parenteral nutrition in critically ill patients
  2. Examine current nutrition guidelines
  3. Evaluate literature supporting delayed parenteral nutrition
1:30 pm

A Case for Vancomycin AUS-Guided Dosing
Morgan King, Pharm.D., PGY2 Pediatric Resident
Peyton Manning Children’s Hospital
​0180-0000-16-809-L01-P

Handout | Equation Sheet
Evaluation

At the end of the session, participants will be able to:

  1. Differentiate between dosing vancomycin based on levels and dosing vancomycin using the area under the curve (AUC)
  2. Evaluate current literature in pediatrics-supporting AUC-guided vancomycin dosing
  3. Apply AUC-guided vancomycin dosing to a pediatric patient case
2:00 pm Akron Children’s Hospital Tour (optional)
2:45 pm

The Use of Probiotics in Pre-term Infants for the Prevention of NEC
Erin Hanley, Pharm.D., PGY2 Pediatric Resident

University of Kentucky Healthcare
​0180-0000-16-810-L01-P

​Handout | Evaluation

At the end of the session, participants will be able to:

  1. Describe the causes of NEC
  2. Understand the mechanism of how probiotics contribute to the prevention of NEC in pre-term infants
  3. Be able to discuss recent research in support of and against probiotic use for NEC prevention
3:15 pm

Atypical Treatment of ICU Delirium
Tia Brandenburg, Pharm.D.
PGY2 Pediatric Resident
University of Kentucky Healthcare
​0180-0000-16-811-L01-P

Handout | Evaluations

At the end of the session, participants will be able to:

  1. Identify therapeutic options used to manage ICU delirium
  2. Discuss efficacy and safety of antipsychotics used to manage ICU delirium
  3. Explain the rationale for the use of quetiapine in managing ICU delirium
3:35 pm

Running on Empty: A discussion on pediatric pharmacist burnout
Laurel Brown, Pharm.D.
Cleveland Clinic Health System
0180-0000-16-812-L04-P

​Handout | Evaluation

At the end of the session, participants will be able to:

  1. Identify factors that contribute to burnout
  2. Recognize signs and symptoms of stress and burnout
  3. Describe strategies to improve professional wellbeing
4:15 pm Conclusion
   

 

Calendar of Events

Upcoming Webinars

On-Demand Programs

 

Fall Conference